Post-neoadjuvant therapy lymph node response in patients with gastric adenocarcinoma.
- 1Universidade Federal do Pará, General and Digestive Surgery Service - Belém (PA), Brazil.
- 2Universidade do Estado do Pará, Center for Biological and Health Sciences - Belém (PA), Brazil.
- 3Universidade Federal do Pará, Medical Oncology Service - Belém (PA), Brazil.
Abstract
Background
Neoadjuvant chemotherapy is recommended as the standard of care for eligible patients with locally advanced resectable gastric adenocarcinoma. However, given the often-late diagnosis of this tumor, understanding post-neoadjuvant therapy lymph node involvement remains a determining factor in the prognosis of these patients.Aims
To evaluate the association between reduced tumor staging after neoadjuvant therapy and lymph node involvement in patients with gastric adenocarcinoma.Methods
This is a retrospective, analytical, observational study based on the medical records of patients who underwent combination therapy from 2018 to 2024. Pre-treatment clinical staging was performed according to institutional protocol, and the relationship between tumor and lymph node staging was established by comparing the initial clinical staging with the post-treatment pathological staging.Results
Eighty-nine patients were included in the analysis, with a reduction in tumor staging observed in 47.2% of cases, based on pathological T-cell analysis. The mean number of affected lymph nodes was significantly higher in non-responder patients compared to responders (5.0±6.3 versus 1.1±2.2; p<0.001). Simple logistic regression analysis identified that the number of affected lymph nodes was associated with the absence of tumor response in univariate analysis, presenting an odds ratio of 1.317 (95%CI 1.099-1.579; p=0.003).Conclusions
The absence of reduction in tumor staging was associated with a higher residual lymph node burden, highlighting the prognostic relevance of lymph node involvement in post-therapeutic evaluation.
Related
- Quantitative Molecular Breast Imaging for Early Prediction of Neoadjuvant Systemic Therapy Response in Locally Advanced Breast Cancer Patients
- Prognostic impact of neoadjuvant therapy and nomogram development in early-stage and locally advanced Siewert type II adenocarcinoma of the esophagogastric junction based on the SEER database
- Survival and Extent of Breast Surgery in Patients with Complete Response After Neoadjuvant Therapy: A Retrospective Analysis from the EUSOMA Database
- Multimodal prediction of neoadjuvant chemotherapy response in locally advanced gastric cancer: a multicenter cohort study
- Neoadjuvant immunotherapy for locally advanced resectable gastric and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.
BibTeX
@article{ishak2026postneoadjuvant,
title = {{Post-neoadjuvant therapy lymph node response in patients with gastric adenocarcinoma.}},
author = {Geraldo Ishak and Luciana Roberta do Vale Corrêa and Thaygo de Azevedo Neves and Ricardo Ormanes Massoud and Ives Uchôa de Azevedo and Pedro Antônio Mufarrej Hage and Williams Fernandes Barra and Paulo Pimentel de Assumpção},
journal = {Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery},
year = {2026},
month = oct,
doi = {10.1590/0102-672020260000049e1978},
url = {https://europepmc.org/article/MED/42912028},
note = {CC BY},
}
RIS
TY - JOUR
TI - Post-neoadjuvant therapy lymph node response in patients with gastric adenocarcinoma.
AU - Geraldo Ishak
AU - Luciana Roberta do Vale Corrêa
AU - Thaygo de Azevedo Neves
AU - Ricardo Ormanes Massoud
AU - Ives Uchôa de Azevedo
AU - Pedro Antônio Mufarrej Hage
AU - Williams Fernandes Barra
AU - Paulo Pimentel de Assumpção
PY - 2026
DA - 2026/10/09
JO - Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery
DO - 10.1590/0102-672020260000049e1978
UR - https://europepmc.org/article/MED/42912028
AB - Background Neoadjuvant chemotherapy is recommended as the standard of care for eligible patients with locally advanced resectable gastric adenocarcinoma. However, given the often-late diagnosis of this tumor, understanding post-neoadjuvant therapy lymph node involvement remains a determining factor in the prognosis of these patients.Aims To evaluate the association between reduced tumor staging after neoadjuvant therapy and lymph node involvement in patients with gastric adenocarcinoma.Methods This is a retrospective, analytical, observational study based on the medical records of patients who underwent combination therapy from 2018 to 2024. Pre-treatment clinical staging was performed according to institutional protocol, and the relationship between tumor and lymph node staging was established by comparing the initial clinical staging with the post-treatment pathological staging.Results Eighty-nine patients were included in the analysis, with a reduction in tumor staging observed in 47.2% of cases, based on pathological T-cell analysis. The mean number of affected lymph nodes was significantly higher in non-responder patients compared to responders (5.0±6.3 versus 1.1±2.2; p<0.001). Simple logistic regression analysis identified that the number of affected lymph nodes was associated with the absence of tumor response in univariate analysis, presenting an odds ratio of 1.317 (95%CI 1.099-1.579; p=0.003).Conclusions The absence of reduction in tumor staging was associated with a higher residual lymph node burden, highlighting the prognostic relevance of lymph node involvement in post-therapeutic evaluation.
SN - 0102-6720
SN - 2317-6326
ER -